Ypsomed : Präsentation der Jahreszahlen 2023/24 (Englisch)

Ypsomed 2023/24 Full-Year Results

Transforming selfcare,

Transforming Ypsomed

Zurich, 22 May 2024

PUBLIC

Important information

The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and

risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and

similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future- oriented statements.

2 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Welcome Samuel Künzli - Chief Financial Officer (as of 01.04.2024)

 2021 - 2024 CFO Feintool

• 2019 - 2020 CFO Stadler Division Switzerland
• 2014 - 2018 CFO Stadler Division Central Europe
• 2012 - 2013 CFO Stadler Minsk

 2008 - 2012 Auditor KPMG

3 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Making selfcare simpler and easier

Improved therapy outcomes for chronic conditions

4 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Solutions for healthcare's biggest challenge are our growth drivers

• Selfcare
  Improving quality of life, therapy adherence and supporting affordable healthcare systems
• Biologics
  Most new-generation drugs with complex active pharmaceutical ingredients have to be injected
• Biosimilars
  Expanding global access to affordable medical care
• Digitization
  Enabling innovative, digital therapy management for optimal therapy outcomes and evidence-based care

5 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Transforming selfcare - Continued high growth

 All growth drivers are lasting, offering tremendous opportunities

 Continuing investments in innovation,

capacity expansion and employees for

both business areas

6 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Transforming Ypsomed - Full focus

7 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Transforming Ypsomed - Both business areas offer tremendous opportunities and require full focus

2022

2023

2024

2025+

2025+

Ypsomed Next transformation with two integrated Business Areas YDS and YDC

Divestment of DiaExpert diabetes retail business in Germany

Divestment of pen needle and BGMS business

Phasing-outof contract manufacturing and transition to production of autoinjectors

Separation into two independent legal entities Ypsomed AG and Ypsomed Diabetes Care AG. Review of strategic options for Ypsomed Diabetes Care AG

8 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Transforming Ypsomed - Both business areas offer tremendous opportunities and require full focus

The YDS business needs full focus and	The YDC business has a clear strategy that
investment capabilities to seize the immense	requires specific capabilities to expand
opportunities in delivery systems	geographically and its innovative portfolio

Separated into two pure play companies, each business

can be more focused and more successful than together

Ypsomed AG will become a pure play B2B	Ypsomed Diabetes Care AG will become a
company, dedicated on growing its leading	pure play B2C company, with patient-centric
position for self-injection therapies	marketing, processes and culture

9 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC

Separation into two fully focused "pure play" companies Project Mercury Phase 1

 Until March 2025, a new company
	Ypsomed Holding AG
Ypsomed Diabetes Care AG (YDC AG)	YPS AG
will be established under the roof of
	YDS		YDC
Ypsomed Holding AG

• Market sounding to get a better understanding of interested parties and the value of Ypsomed's diabetes care business

		Corporate Areas
		Subsidiaries
YPS AG					YDC AG
		YDS						YDC
		Corporate				Selected
		Areas						Roles
		Subsidiaries			Subsidiaries

10 | Ypsomed Holding AG | 2023/24 Full-Year Results

PUBLIC